Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

NCT ID: NCT06419608

Last Updated: 2026-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

336 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-28

Study Completion Date

2025-11-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BHV-7000

Group Type EXPERIMENTAL

BHV-7000

Intervention Type DRUG

BHV-7000 75 mg taken once daily for 6 weeks

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo taken once daily for 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BHV-7000

BHV-7000 75 mg taken once daily for 6 weeks

Intervention Type DRUG

Placebo

Matching placebo taken once daily for 6 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects experiencing a moderate to severe episode of depression.
2. Subjects experiencing a current episode of depression for at least 2 months.
3. Subjects must be willing to discontinue all psychotropic medications (other medications to treat depression) before entering the study.
4. Male and Female participants 18 to 75 years of age at the time of consent.
5. Body Mass Index (BMI) must be ≥ 18 kg/m2 and ≤ 35 kg/m2.

Exclusion Criteria

1. Subjects taking more than 2 medications (other than benzodiazepines and medications targeting insomnia) to treat depression at the screening visit.
2. Subjects with a history of bipolar disorder, schizophrenia, or other neuropsychiatric conditions that may interfere with the conduct of the study.
3. Subjects with a history of medical conditions that may interfere with the conduct of the study.
4. Females who are pregnant, breastfeeding or planning to become pregnant.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biohaven Therapeutics Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IMA Clinical Research

Phoenix, Arizona, United States

Site Status

Pillar Clinical Research, LLC

Little Rock, Arkansas, United States

Site Status

WIRG

Little Rock, Arkansas, United States

Site Status

WRN

Rogers, Arkansas, United States

Site Status

Advanced Research Center, Inc.

Anaheim, California, United States

Site Status

CIT LA

Bellflower, California, United States

Site Status

IPMG

Chino, California, United States

Site Status

WR-PRI Encino

Encino, California, United States

Site Status

Collaborative Neuroscience Research, LLC (CenExel - CNS)

Garden Grove, California, United States

Site Status

CalNeuro Research Group

Los Angeles, California, United States

Site Status

Excell Research, Inc.

Oceanside, California, United States

Site Status

NRC Research Institute

Orange, California, United States

Site Status

Anderson Clinical Research

Redlands, California, United States

Site Status

CIT IE

Riverside, California, United States

Site Status

Lumos Clinical Research Center

San Jose, California, United States

Site Status

Stanford

Stanford, California, United States

Site Status

Cenexel CNS

Torrance, California, United States

Site Status

Pacific Clinical Research Management Group

Upland, California, United States

Site Status

Sunwise Clinical Research

Walnut Creek, California, United States

Site Status

MCB Clinical Research Centers

Colorado Springs, Colorado, United States

Site Status

UConn Health

Farmington, Connecticut, United States

Site Status

Optum Behavioral Care of Connecticut, PC dba Comprehensive Psychiatric Care of Connecticut

Norwich, Connecticut, United States

Site Status

Clinical Neuroscience Solutions, Inc

Jacksonville, Florida, United States

Site Status

Floridian Neuroscience Institute

Miami Lakes, Florida, United States

Site Status

Clinical Neuroscience Solutions, Inc.

Orlando, Florida, United States

Site Status

K2 Medical Research

Tampa, Florida, United States

Site Status

Neuroscience Research Institute

West Palm Beach, Florida, United States

Site Status

CenExel iResearch, LLC

Decatur, Georgia, United States

Site Status

CenExel iResearch, LLC

Savannah, Georgia, United States

Site Status

Uptown Research Institute

Chicago, Illinois, United States

Site Status

Revive Research Institute, Inc.

Elgin, Illinois, United States

Site Status

Collective Medical Research

Overland Park, Kansas, United States

Site Status

Delricht Research

New Orleans, Louisiana, United States

Site Status

Headlands Pharmasite

Baltimore, Maryland, United States

Site Status

CBH Health

Gaithersburg, Maryland, United States

Site Status

Copley Clinical

Boston, Massachusetts, United States

Site Status

Boston Clinical Trials

Boston, Massachusetts, United States

Site Status

Adams Clinical

Watertown, Massachusetts, United States

Site Status

Precise Clinical Research

Flowood, Mississippi, United States

Site Status

Arch Clinical Trials

St Louis, Missouri, United States

Site Status

IMA Clinical Research

Las Vegas, Nevada, United States

Site Status

Bio Behavioral Health

Toms River, New Jersey, United States

Site Status

SPRI Clinical Trials, LLC

Brooklyn, New York, United States

Site Status

Neurobehavioral Research, Inc

Cedarhurst, New York, United States

Site Status

Bioscience Research LLC

Mount Kisco, New York, United States

Site Status

Berman Clinical

New York, New York, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

The Medical Research Network, LLC

New York, New York, United States

Site Status

RBA

Staten Island, New York, United States

Site Status

Lehigh Center for Clinical Research

Allentown, Pennsylvania, United States

Site Status

Suburban Research Associates

Media, Pennsylvania, United States

Site Status

Scranton Medical Institute

Moosic, Pennsylvania, United States

Site Status

Coastal Carolina Research Center

North Charleston, South Carolina, United States

Site Status

Donald J. Garcia, MD, PA dba Austin Clinical Trial Partners

Austin, Texas, United States

Site Status

FutureSearch Trials of Dallas

Dallas, Texas, United States

Site Status

Relaro Medical Trials, LLC

Dallas, Texas, United States

Site Status

InSite Clinical Research, LLC

DeSoto, Texas, United States

Site Status

Red Oak Psychiatry Associates, PA

Houston, Texas, United States

Site Status

Aim Trials

Plano, Texas, United States

Site Status

Grayline Research Center

Wichita Falls, Texas, United States

Site Status

Alpine Reseach Organization

Clinton, Utah, United States

Site Status

Northwest Clinical Research Center

Bellevue, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BHV7000-305

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.